Full Title
A Phase Ib/II Study of the Mirdametinib in Combination with Palbociclib in Patients with Advanced Dedifferentiated LiposarcomaPurpose
Researchers want to find the best dose of mirdametinib to give with palbociclib to treat dedifferentiated liposarcoma. The people in this study have liposarcoma that has spread or keeps growing even after treatment.
Mirdametinib blocks proteins called MEK1 and MEK2, which play an important role in cancer cell growth and survival. By blocking MEK1 and MEK2, mirdametinib may slow or stop the growth of your cancer.
Palbociclib inhibits the CDK4 and CDK6 kinase proteins. Kinase inhibitors target cancer cell proteins. When these proteins are blocked, your cancer may stop growing or it may grow more slowly, and tumors may shrink. Both mirdametinib and palbociclib are taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have dedifferentiated liposarcoma that metastasized (spread) or came back after treatment.
- Have recovered from the serious side effects of previous treatments before taking the study therapy.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Evan Rosenbaum’s office at 646-888-4159.